P2D Bioscience (P2D) is a specialty pharmaceutical company focused on developing innovative drugs that fulfill unmet medical needs in the treatment of central nervous system (CNS) and pulmonary disorders including attention deficit/hyperactivity disorder (ADHD), obesity, anxiety, depression, Alzheimer’s disease, traumatic brain injury and chronic obstructive pulmonary disease (COPD). At P2D, our experienced drug development team utilizes our in-depth understanding of the clinical treatment of CNS disorders and neurodegenerative diseases to efficiently build a product portfolio of therapeutics with an improved likelihood for clinical success. Our goal is to advance a product candidate through preclinical development and clinical proof-of-concept by producing powerful and compelling clinical data and then seeking partners to complete the clinical development and commercialization process. P2D currently has a pipeline of nine drug candidates to treat ADHD, obesity and diabetes, Alzheimer’s disease, traumatic brain injury and COPD.
Looking for a particular P2D Bioscience employee's phone or email?
P2D Bioscience Questions
The P2D Bioscience annual revenue was $1 million in 2026.
Frank Zemlan is the President of P2D Bioscience.
1 people are employed at P2D Bioscience.
P2D Bioscience is based in Cincinnati, Ohio.
The NAICS codes for P2D Bioscience are [32541, 3254, 32, 325].
The SIC codes for P2D Bioscience are [283, 28].
Top P2D Bioscience Employees
-
Frank Zemlan
President at P2D Bioscience
Cincinnati, OH, US13
Related Companies
